A5021722390- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Cancer therapeutics and mechanisms
- Peptidase Inhibition and Analysis
- Myasthenia Gravis and Thymoma
- Cancer Treatment and Pharmacology
- Cancer, Hypoxia, and Metabolism
- Pituitary Gland Disorders and Treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Inflammatory Biomarkers in Disease Prognosis
- Neutropenia and Cancer Infections
- PI3K/AKT/mTOR signaling in cancer
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Radiomics and Machine Learning in Medical Imaging
- Neuroblastoma Research and Treatments
- Glycosylation and Glycoproteins Research
- Cancer Research and Treatments
- Cardiac tumors and thrombi
Kitasato University
2016-2025
Weatherford College
2021
Nihon University
2021
Hyogo Medical University
2021
Riau University
2019
Fukujuji Hospital
2019
Grantham Hospital
2019
Kitasato University Hospital
2012-2018
Shizuoka Cancer Center
2007-2011
Government of the Republic of Korea
2008
The detection of circulating tumor cells (CTCs) in peripheral blood is currently an important field study. Detection CTCs by the OBP-401 assay (TelomeScan®) has previously been reported to be useful diagnosis, prognosis and evaluation therapeutic efficacy breast gastric cancer. aim present study was evaluate as a novel method detecting small cell lung cancer (SCLC) patients whether CTC count associated with prognosis. Prospectively, 30 consecutively diagnosed SCLC who had commenced...
Oligometastasis is a state in which cancer patients have limited number of metastatic tumors; with oligometastases survive longer than those polymetastases. Extensive disease (ED)-small cell lung (SCLC) considered systemic and poor survival. This study investigated whether the concept prognostic factor also applicable to ED-SCLC.We performed retrospective 141 consecutive ED-SCLC between 2008 2016. The were divided into four subgroups: group 1; solitary site one organ (n = 31), 2; 2-5 sites...
Immunotherapy can become a crucial therapeutic option to improve the prognosis of patients with non-small-cell lung cancer (NSCLC). Here, we evaluated impact programmed cell death ligand-1 (PD-L1) expression in surgically resected NSCLCs.We estimated PD-L1 229 consecutive NSCLC specimens using rabbit polyclonal antibodies human SP263 immunohistochemical assay and for potential associations clinicopathological parameters survival time.PD-L1 was significantly higher tumors from men or current...
Although osimertinib is a promising therapeutic agent for advanced epidermal growth factor receptor (EGFR) mutation-positive lung cancer, the incidence of pneumonitis particularly high among Japanese patients receiving drug. Furthermore, safety and efficacy subsequent anticancer treatments, including EGFR-tyrosine kinase inhibitor (TKI) rechallenge, which are to be administered after recovery, remain unclear. This study investigated EGFR-TKI rechallenge in who experienced first-line...
Background: Small cell lung cancer (SCLC) is typically categorized according to disease extent as limited or extensive, and utility of the 8th TNM classification, recommended for staging, which demonstrates a strong association with non-small-cell (NSCLC) management, remains unclear. Methods: This retrospective study included 277 consecutive SCLC patients treated at single institution between 2008 2016. Results: According currently used two-stage system, 186 (65.7%) were classified having...
S100A16, a promising candidate as prognostic marker for platinum-based adjuvant chemotherapy in resected lung adenocarcinoma Ken Katono,1 Yuichi Sato,2 Makoto Kobayashi,3 Ryo Nagashio,2 Shinichiro Ryuge,1 Satoshi Igawa,1 Masaaki Ichinoe,4 Yoshiki Murakumo,4 Saegusa,4 Noriyuki Masuda1 1Department of Respiratory Medicine, School 2Department Molecular Diagnostics, Allied Health Sciences, 3Department Applied Tumor Pathology, Graduate Medical 4Department Kitasato University, Minami-ku,...
The efficacy of combined modality therapy is evaluated for patients with extensive-stage (ES) small cell lung cancer (SCLC). This study prognostic factors affecting the risk thoracic progression in ES-SCLC likely to undergo radiotherapy chemotherapy.A retrospective review who had received systemic chemotherapy at our hospital was performed. Tumor size, metastatic sites, and laboratory data diagnosis were as potential factors. In without pleural dissemination, rate after initial...
NAP1L1 is a key regulator of embryonic neurogenesis but its role in lung cancer remains unexplored. In this study, we investigated the relationship between expression and clinicopathological parameters prognosis non-small cell patients. To end, tumor samples was evaluated by immunohistochemistry. significantly associated with reduced differentiation (P = 0.00014), higher pathological TNM stages < 0.00001), lymph node metastasis intrapulmonary 0.02955), lymphatic invasion 0.00019), vascular...
Traditionally, relapsed SCLC has been classified as "sensitive" or "refractory" on the basis of cutoff values (60 90 d) for duration between last chemotherapy and disease progression. Nevertheless, these are not derived from rigorous analytical methods, their applicability to contemporary treatments remains uncertain.
Purpose: A T790M of the epidermal growth factor receptor (EGFR) is most frequently encountered mutation conferring acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). The aim this study was assess differential clinical outcomes osimertinib therapy NSCLC patients with according type activating mutation, ie, exon 19 deletion or L858R point mutation. Patients and methods: prospective observational cohort conducted evaluate efficacy safety a major...
The purpose of this study was to evaluate the efficacy pemetrexed monotherapy in previously treated patients with advanced non-small cell lung cancer (NSCLC) including salvage treatment, and whether thymidylate synthase (TS) expression is a predictor for efficacy. Hundred four NSCLC who received were retrospectively evaluated clinical toxicity. If available, tissue specimens also analyzed immunohistochemically TS expression. patients’ median age 65 years (range: 43–82). An overall response...
Several studies have reported that S100A14 plays important roles during different steps of the tumorigenic process and tumor progression several types cancer. The aim present study was to investigate clinicopathological prognostic significance functional in lung adenocarcinoma.S100A14 expression immunohistochemically studied 166 consecutive resected adenocarcinomas, its correlation with parameters evaluated. Functional adenocarcinoma were investigated based on invasion migration assays a...